Asia Pacific Key To Speeding Up Global Drug Development, Says Quintiles VP Anand Tharmaratnam (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Globalization of clinical trials is perhaps Asia's main role in advancing the pharmaceutical industry, says Quintiles Asia Pacific Head of Clinical Development Anand Tharmaratnam, who discussed innovation in Asia Pacific with PharmAsia News' Australia Bureau. Key to that innovation is a lack of legacy informationin that the past is not holding the industry back, and virtual opportunitiesand private/public cooperative partnerships offer ripe benefits.
You may also be interested in...
Quintiles Asia Strategic Planning Director Simranjit Singh On Korea’s Clinical Trial Strategy: An Interview With PharmAsia News
The CRO exec discusses Korea’s expanding role in global clinical trials and the rising interest among MNCs for conducting trials in Korea, as evidenced by Pfizer’s Xalkori.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.